Angel News

Back to Homepage

26th April 2018

Downing and BioScience Managers invest £1.14 million in ADC Biotechnology

London-based investment management firm, Downing LLP, and BioScience Managers Limited, the international healthcare investment firm and advisers to the Downing FOUR VCT, have invested £1.14 million in Wales-based ADC Biotechnology Ltd.

ADC Biotechnology is creating innovative new technology, which aims to speed up, simplify and significantly lower the costs of the processes involved in the production of new antibody drug 

23rd April 2018

Albion backed Orchard Therapeutics signs strategic deal with GSK



GSK and Orchard Therapeutics have announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities in cell and gene therapies, with a focus on oncology.

19th April 2018

Touch Biometrix secures investment from Deepbridge Capital

Touch Biometrix, a UK company aiming to change the way we interact with technology for user authentication are pleased to announce they have received seed investment from Deepbridge Capital.

19th April 2018

Zelluna Immunotherapy appoints Arjan Roozen as CTO

Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, has announced the appointment of Arjan Roozen as chief technology officer (CTO). 

19th April 2018

LNC Therapeutics appoints new CEO

LNC Therapeutics, a French biotech company specializing in research and development for gut microbiome-based drugs, has announced the appointment of Dr. Georges Rawadi as its new CEO.  Jean-Luc Treillou, his predecessor, will become Chairman of the Board of Directors on July 1st.

19th April 2018

Pharmacy2U secures further investment

Pharmacy2U, the UK’s largest NHS online pharmacy, has secured a further £40 million investment to support the rapid growth of its online 

13th April 2018

TrakCel to supply UK’s Northern Alliance cell therapy partnership

TrakCel, the industry-leading software developer for cell and gene therapy supply chain tracking and orchestration, announces today it will be the organization responsible for tracking and documentation of cell and gene therapy products for the Northern Alliance Advanced Therapies Treatment Centre. 

6th April 2018

Kaiku Health raises €4.4 million

Finnish digital health company Kaiku Health Oy, which provides intelligent patient monitoring software for healthcare providers across Europe, has closed a €4.4 million funding round. The investment was led by Debiopharm Innovation Fund SA and Tesi with participation from Prodeko Ventures Oy and existing investors Reaktor Ventures Oy, Metsola Ventures Oy, and Athensmed Oy.

29th March 2018

LetsGetChecked Raises $12 million

LetsGetChecked, the medical health testing platform that allows customers to access regulated laboratory testing and self-test from the comfort of home.

28th March 2018

Cambridge firm Glyconics signs agreement with Ghent University

Glyconics has signed an exclusive licensing deal with Ghent University in Belgium for its proprietary method for the measurement of Diabetes 

21st March 2018

Archangels and SIB invest £2m in drug delivery company BDD

Archangels and Scottish Investment Bank have invested £2 million in Bio-Images Drug Delivery Limited (BDD). 


19th March 2018

Angel Deal of the Month - Incereb

Hats off to HBAN who funded an angel deal just 48 hours after the pitch.

How did this investment which is possibly the speediest investment ever (let me know if you know of a quicker one) happen?  HBAN explained that it was partly because with previous investors, including HBAN angels, already in the deal, all the due diligence was in place.

Items of 33NEXT

Back to Homepage